The Multifunction Of miR-218-5p-Cx43 Axis In Breast Cancer
Open Access
- 1 October 2019
- journal article
- retracted article
- Published by Taylor & Francis Ltd in OncoTargets and Therapy
- Vol. ume 12, 8319-8328
- https://doi.org/10.2147/OTT.S218524
Abstract
Background: Gemcitabine is proven to be the first-line standard treatment of breast cancers. Yet, little is known involving gemcitabine resistance and remains largely to be elucidated. Materials and methods: We evaluated the expression of Cx43 in gemcitabine-resistant cells and parental cells by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot analyses. Dual-luciferase reporter assay was applied to examine the epigenetic regulator of Cx43. The role of miR-218-5p-Cx43 axis on cell cytotoxicity, cell proliferation, colony formation, chemoresistance and migration was detected via mammalian expression vector and small short RNA (shRNA) transfection in vitro. Results: In this study, we found that Cx43 expression levels were significantly lower in gemcitabine-resistant cells than in the parental cells. On deep investigation of the epigenetic regulation of Cx43, a few miRNA candidates targeting Cx43 were derived. Through dual-luciferase reporter assay, Cx43 was proved to be a direct target of miR-218-5p. Besides, qPCR, Western blot demonstrated an inverse correlation between miR-218-5p and Cx43 expression in breast cancer cells, thus forming the miR-218-5p-Cx43 axis. Notably, miR-218-5p-Cx43 axis was found to be involved in the process of gemcitabine chemoresistance, cell proliferation and migration in breast cancer cells. Conclusion: Our findings suggested that miR-218-5p-Cx43 axis was versatile and indicated significant potency in breast cancer cells. More importantly, miR-218-5p-Cx43 axis might be valuable in translational medicine, with therapeutic and prognostic information.Keywords
This publication has 34 references indexed in Scilit:
- The Potential for microRNA Therapeutics and Clinical ResearchFrontiers in Genetics, 2019
- Connexins in cancer: bridging the gap to the clinicOncogene, 2019
- Classification, Treatment Strategy, and Associated Drug Resistance in Breast CancerClinical Breast Cancer, 2016
- MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expressionOncotarget, 2016
- Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathwayOncogene, 2016
- miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancerBreast Cancer Research and Treatment, 2015
- Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trialThe Lancet Oncology, 2015
- Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancerEuropean Journal of Pharmacology, 2014
- Silencing of miRNA-218 promotes migration and invasion of breast cancer via Slit2-Robo1 pathwayBiomedicine & Pharmacotherapy, 2012
- Clinical pharmacology and pharmacogenetics of gemcitabineDrug Metabolism Reviews, 2009